


P1 1157297



THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME;

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office

April 27, 2004


THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.

APPLICATION NUMBER: 60/443,650

FILING DATE: January 30, 2003

RELATED PCT APPLICATION NUMBER: PCT/US04/02366

By Authority of the
COMMISSIONER OF PATENTS AND TRADEMARKS



A handwritten signature in ink, appearing to read "M. Sias".

M. SIAS
Certifying Officer

**PRIORITY
DOCUMENT**

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

01/30/03

J1064 U.S. PTO

"EXPRESS MAIL CERTIFICATE""Express Mail" Mailing Label Number **EL808221248US**Date Of Deposit: **January 30, 2003**

I Herby Certify That This Paper Or Fee Is Being Deposited With The United States Postal Service "Express Mail Post Office To Addressee" Service Under 37 CFR 1.10 On The Date Indicated Above And Is Addressed To: Assistant Commissioner for Patents, Washington, D.C. 20231.

Name Of Person Mailing Paper Or Fee

(Type Or Print) **DAWN TRIGG**

Signature

PROVISIONAL APPLICATION COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION for PATENT under 37 CFR 1.53(c).

Docket No.

PU60031P

INVENTOR(s) / APPLICANT(s)			
Last Name	First Name	Middle Initial	Residence (City and Either State or Foreign Country)
KERNS	Jeffrey		King of Prussia, Pennsylvania
JIN	Qi		King of Prussia, Pennsylvania
NIE	Hong		King of Prussia, Pennsylvania
WAN	Zehong		King of Prussia, Pennsylvania
ZHU	Chongjie		King of Prussia, Pennsylvania

TITLE OF THE INVENTION (280 characters max)

QUINOLINE DERIVATIVES AS NK-2 AND NK-3 RECEPTOR ANTAGONISTS

Correspondence Address:

GLAXOSMITHKLINE

Corporate Intellectual Property - UW2220

709 Swedeland Road

King of Prussia

Telephone No. 610-270-7339

Facsimile No. 610-270-5090

State	PA	Zip Code	19406-0939	Country	United States of America
-------	----	----------	------------	---------	--------------------------

ENCLOSED APPLICATION PARTS (check all that apply)

☒ Specification

Number of Pages

52Total Number of Pages = **53**☒ Abstract

Number of Pages

1☐ Drawings

Number of Sheets

☐ Other (specify)

METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT

☒ The Commissioner is hereby authorized to charge filing fees and credit Deposit Account No. 19-2570PROVISIONAL FILING
FEE AMOUNT (\$)**\$160.00**Respectfully submitted,
Signature:

Laura K. Madden

Date:

01/30/03

Registration No.:

48,352☐ Additional inventors are being named on separately numbered sheets attached hereto.**PROVISIONAL APPLICATION FILING ONLY**

SEND TO: Assistant Commissioner for Patents, Box Provisional Application, Washington, D.C. 20231.

**20462**

PATENT TRADEMARK OFFICE

Quinoline Derivatives as NK-2 and NK-3 Receptor Antagonists

5 The present invention relates to novel compounds, in particular to novel quinoline derivatives, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds and to the use of such compounds in medicine.

The mammalian peptide Neurokinin B (NKB) belongs to the Tachykinin (TK) peptide family which also include Substance P (SP) and Neurokinin A (NKA). Pharmacological and molecular biological evidence has shown the existence of three subtypes of TK receptor (NK₁, NK₂ and NK₃) and NKB binds preferentially to the NK₃ receptor although it also recognizes the other two receptors with lower affinity (Maggi et al, 1993, *J. Auton. Pharmacol.*, 13, 23-93).

Selective peptidic NK₃ receptor antagonists are known (Drapeau, 1990 *Regul. Pept.*, 31, 125-135), and findings with peptidic NK₃ receptor agonists suggest that NKB, by activating the NK₃ receptor, has a key role in the modulation of neural input in airways, skin, spinal cord and nigro-striatal pathways (Myers and Undem, 1993, *J. Physiol.*, 470, 665-679; Counture et al., 1993, *Regul. Peptides*, 46, 426-429; Mccarson and Krause, 1994, *J. Neurosci.*, 14 (2), 712-720; Arenas et al. 1991, *J. Neurosci.*, 11, 2332-8). However, the peptide-like nature of the known antagonists makes them likely to be too labile from a metabolic point of view to serve as practical therapeutic agents.

International Patent Application, Publication Number WO 00/58307 describes a series of aryl fused 2,4-disubstituted pyridines, such as naphthyridine derivatives, which are stated to exhibit biological activity as NK₃ receptor antagonists.

30 The compounds of the present invention are quinoline derivatives. Other quinoline derivatives have been described previously as selective NK₃ antagonists. For example, International Patent Application, Publication Numbers, WO 95/32948

and WO 96/02509 describe a series of selective and potent NK₃ receptor antagonists.

International Patent Application, Publication Number WO 00/64877 describes a series of 2-aminoquinolinecarboxamides as neurokinin receptor ligands.

5 International Patent Application, Publication Number, WO 00/58303 describes a series of 4-substituted quinoline derivatives which are stated to be NK₃ and/or GABA(A) receptor ligands. Such compounds are characterized by the presence of a nitrogen-containing heterocyclic moiety at the C(4) position of the quinoline ring.

10 International Patent Application, Publication Numbers, WO 97/21680, WO 98/52942, WO 00/31037, WO 00/31038, WO02/38547, WO 02/38548, WO 02/43734, WO 02/44154, and WO 02/44165 describe compounds which have biological activity as combined NK₃ and NK₂ receptor antagonists.

We have now discovered a further novel class of non-peptide NK₃ antagonists which are far more stable from a metabolic point of view than the known peptidic NK₃ receptor antagonists and are of potential therapeutic utility. These compounds also have NK₂ antagonist activity and are therefore considered to be of potential use in the prevention and treatment of a wide variety of clinical conditions, which are characterised by overstimulation of the Tachykinin receptors, in particular NK₃ and NK₂.

These conditions include respiratory diseases, such as chronic obstructive pulmonary disease (COPD), asthma, airway hyper-reactivity, cough; inflammatory diseases such as inflammatory bowel disease, psoriasis, fibrositis, osteoarthritis, rheumatoid arthritis and inflammatory pain; neurogenic inflammation or peripheral neuropathy, allergies such as eczema and rhinitis; ophthalmic diseases such as ocular inflammation, conjunctivitis, vernal conjunctivitis and the like; cutaneous diseases, skin disorders and itch, such as cutaneous wheal and flare, contact dermatitis, atopic dermatitis, urticaria and other eczematoid dermatitis; adverse immunological reactions such as rejection of transplanted tissues and disorders related to immune enhancement or suppression such as systemic lupus erythematosus; gastrointestinal (GI) disorders and diseases of the GI tract such as disorders associated with the neuronal control of viscera such as ulcerative colitis,

Crohn's disease, irritable bowel syndrome (IBS), gastro-esophageal reflux disease (GERD); urinary incontinence and disorders of the bladder function; renal disorders; increased blood pressure, proteinuria, coagulopathy and peripheral and cerebral oedema following pre-eclampsia in pregnancies (hereinafter referred to as the
5 'Primary Conditions').


Certain of these compounds also show CNS activity and hence are considered to be of particular use in the treatment of disorders of the central nervous system such as anxiety, depression, psychosis and schizophrenia; neurodegenerative disorders such as AIDS related dementia, senile dementia of the Alzheimer type,
10 Alzheimer's disease, Down's syndrome, Huntington's disease, Parkinson's disease, movement disorders and convulsive disorders (for example epilepsy); demyelinating diseases such as multiple sclerosis and amyotrophic lateral sclerosis and other neuropathological disorders such as diabetic neuropathy, AIDS related neuropathy, chemotherapy-induced neuropathy and neuralgia; addiction disorders such as
15 alcoholism; stress related somatic disorders; reflex sympathetic dystrophy such as shoulder/hand syndrome; dysthymic disorders; eating disorders (such as food intake disease); fibrosing and collagen diseases such as scleroderma and eosinophilic fasciitis; disorders of the blood flow caused by vasodilatation and vasospastic diseases such as angina, migraine and Reynaud's disease and pain or nociception, for
20 example, that is attributable to or associated with any of the foregoing conditions especially the transmission of pain in migraine, (hereinafter referred to as the 'Secondary Conditions').

The compounds of formula (I) are also considered to be useful as diagnostic tools for assessing the degree to which neurokinin-3 and neurokinin-2 receptor
25 activity (normal, overactivity or underactivity) is implicated in a patient's symptoms.

Certain compounds of the present invention have also been found to exhibit surprisingly advantageous pharmacological properties.

DETAILED DESCRIPTION OF THE INVENTION

30 According to the present invention, there is provided a compound of formula (I) below or a pharmaceutically acceptable salt or solvate thereof:



wherein:

R₁ is H or substituted or unsubstituted (C₁₋₆)alkyl;

5

R₂ is substituted or unsubstituted aryl, (C₃₋₇)cycloalkyl, or heterocycle;

R₃ is H or substituted or unsubstituted (C₁₋₆)alkyl, (C₃₋₇)cycloalkyl, aryl or heterocycle;

10

A is NR₈ or O;

R₈ is H or substituted or unsubstituted (C₁₋₆)alkyl;

15 R₄ is substituted or unsubstituted heterocycle;

R₅ is H or up to three substituents independently selected from the list consisting of alkyl, alkenyl, aryl, alkoxy, or a hydroxylated derivative thereof, hydroxy, halogen, nitro, cyano, carboxy, alkylcarboxy, alkylcarboxyalkyl, haloalkyl, amino or mono- or dialkylamino; or R₅ represents a bridging moiety which is arranged to bridge two adjacent ring atoms wherein the bridging moiety comprises alkyl or dioxyalkylene;

20

R₆ is H or halo;

25 R₇ is oxo;

n is 1 to 4.

Preferably, R₁ is methyl.

- 5 Suitably, R₂ is substituted or unsubstituted aryl or (C₃₋₇)cycloalkyl. Preferably, R₂ is substituted or unsubstituted phenyl or cyclohexyl. Most preferably R₂ is unsubstituted phenyl or cyclohexyl.

Preferably R₃ is (C₁₋₆)alkyl or heterocycle. Methyl is a most preferred R₃ group.

- 10 Other most preferred R₃ groups are substituted and unsubstituted morpholino, piperazine, pyrrole, piperidine, thiophene, imidazole, and pyrazole.

Preferably R₈ is H or methyl.

- 15 Preferably R₄ is substituted or unsubstituted 2-thienyl or 3-thienyl. Most preferably R₄ is unsubstituted 2-thienyl or 3-thienyl.

Preferably R₅ is H or fluoro.

- 20 Preferably R₆ is H or fluoro.

Preferably n is 1.

- 25 Preferred compounds of formula (I) which are of special interest as agents useful in the treatment and/or prophylaxis of conditions which are characterised by overstimulation of the Tachykinin receptors, in particular NK₃ and NK₂, are:

3-(4-Dimethylcarbamoylmethyl-3-oxo-piperazin-1-ylmethyl)-2-thiophen-2-yl-quinoline-4-carboxylic acid ((S)-1-cyclohexyl-ethyl)-amide,

- 30 3-[4-(2-Morpholin-4-yl-2-oxo-ethyl)-3-oxo-piperazin-1-ylmethyl)-2-thiophen-2-yl-quinoline-4-carboxylic acid ((S)-1-cyclohexyl-ethyl)-amide,

- 3-[3-Oxo-4-(2-oxo-2-piperazin-1-yl-ethyl)-piperazin-1-ylmethyl]-2-thiophen-2-yl-quinoline-4-carboxylic acid ((S)-1-cyclohexyl-ethyl)-amide,
- 5 3-(4-Carbamoylmethyl-3-oxo-piperazin-1-ylmethyl)-2-thiophen-2-yl-quinoline-4-carboxylic acid ((S)-1-cyclohexyl-ethyl)-amide,
- 3-{4-[2-(4-Methyl-piperazin-1-yl)-2-oxo-ethyl]-3-oxo-piperazin-1-ylmethyl}-2-thiophen-2-yl-quinoline-4-carboxylic acid ((S)-1-cyclohexyl-ethyl)-amide,
- 10 3-[3-Oxo-4-(2-oxo-piperidin-1-yl-ethyl)-piperazin-1-ylmethyl]-2-thiophen-2-yl-quinoline-4-carboxylic acid ((S)-1-cyclohexyl-ethyl)-amide,
- 15 3-[3-Oxo-4-(2-oxo-pyrrolidin-1-yl-ethyl)-piperazin-1-ylmethyl]-2-thiophen-2-yl-quinoline-4-carboxylic acid ((S)-1-cyclohexyl-ethyl)-amide,
- 3-[4-(3-Morpholin-4-yl-3-oxo-propyl)-3-oxo-piperazin-1-ylmethyl]-2-thiophen-2-yl-quinoline-4-carboxylic acid ((S)-1-cyclohexyl-ethyl)-amide,
- 20 3-[4-(2-Morpholin-4-yl-2-oxo-ethyl)-2-oxo-piperazin-1-ylmethyl]-2-thiophen-2-yl-quinoline-4-carboxylic acid ((S)-1-cyclohexyl-ethyl)-amide,
- 3-(4-Dimethylcarbamoylmethyl-2-oxo-piperazin-1-ylmethyl)-2-thiophen-2-yl-quinoline-4-carboxylic acid ((S)-1-cyclohexyl-ethyl)-amide,
- 25 6-Fluoro-3-[4-(2-morpholin-4-yl-2-oxo-ethyl)-3-oxo-piperazin-1-ylmethyl]-2-thiophen-2-yl-quinoline-4-carboxylic acid ((S)-1-cyclohexyl-ethyl)-amide,
- 30 6-Fluoro-3-[3-oxo-4-(2-oxo-2-pyrrolidin-1-yl-ethyl)-piperazin-1-ylmethyl]-2-thiophen-2-yl-quinoline-4-carboxylic acid ((S)-1-cyclohexyl-ethyl)-amide,


3-{4-[2-((R)-2-Hydroxymethyl-pyrrolidin-1-yl)-2-oxo-ethyl]-3-oxo-piperazin-1-ylmethyl}-2-thiophen-2-yl-quinoline-4-carboxylic acid ((S)-1-cyclohexyl-ethyl)-amide,

- 5 3-(4-{[(2,5-Dimethyl-2H-pyrazol-3-ylmethyl)-carbamoyl]-methyl}-3-oxo-piperazin-1-ylmethyl)-2-thiophen-2-yl-quinoline-4-carboxylic acid ((S)-1-cyclohexyl-ethyl)-amide,


- 10 3-(4-{[(5-Methyl-1H-imidazol-2-ylmethyl)-carbamoyl]-methyl}-3-oxo-piperazin-1-ylmethyl)-2-thiophen-2-yl-quinoline-4-carboxylic acid ((S)-1-cyclohexyl-ethyl)-amide, and

- 15 3-{4-[(Methyl-thiophen-2-ylmethyl)-carbamoyl]-methyl}-3-oxo-piperazin-1-ylmethyl)-2-thiophen-2-yl-quinoline-4-carboxylic acid ((S)-1-cyclohexyl-ethyl)-amide, or a pharmaceutically acceptable salt thereof.

The compounds of formula (I) may have at least one asymmetric centre - for example the carbon atom labelled with an asterisk (*) in the compound of formula (I) - and therefore may exist in more than one stereoisomeric form. The invention extends to all such stereoisomeric forms and to mixtures thereof, including
20 racemates. In particular, the invention includes compounds wherein the asterisked carbon atom in formula (I) has the stereochemistry shown in formula (Ib):



- 25 wherein R₁, R₂, R₄, R₅, and R₆ are as defined in relation to formula (I), and X represents the moiety



wherein R₇ and R₃ are as defined in relation to formula (I).

5 The compounds of formula (I) or their salts or solvates are preferably in pharmaceutically acceptable or substantially pure form. By pharmaceutically acceptable form is meant, *inter alia*, having a pharmaceutically acceptable level of purity excluding normal pharmaceutical additives such as diluents and carriers, and including no material considered toxic at normal dosage levels.

10 A substantially pure form will generally contain at least 50% (excluding normal pharmaceutical additives), preferably 75%, more preferably 90% and still more preferably 95% of the compound of formula (I) or its salt or solvate.

One preferred pharmaceutically acceptable form is the crystalline form, including such form in pharmaceutical composition. In the case of salts and solvates
15 the additional ionic and solvent moieties must also be non-toxic.

Suitable salts are pharmaceutically acceptable salts.

Suitable pharmaceutically acceptable salts include the acid addition salts with the conventional pharmaceutical acids, for example maleic, hydrochloric, hydrobromic, phosphoric, acetic, fumaric, salicylic, citric, lactic, mandelic, tartaric,
20 succinic, benzoic, ascorbic and methanesulphonic.

Suitable pharmaceutically acceptable salts include salts of acidic moieties of the compounds of formula (I) when they are present, for example salts of carboxy groups or phenolic hydroxy groups.

25 Suitable salts of acidic moieties include metal salts, such as for example aluminium, alkali metal salts such as lithium, sodium or potassium, alkaline earth metal salts such as calcium or magnesium and ammonium or substituted ammonium salts, for example those with lower alkylamines such as triethylamine, hydroxy alkylamines such as 2-hydroxyethylamine, bis-(2-hydroxyethyl)-amine or tri-(2-hydroxyethyl)-amine, cycloalkylamines such as bicyclohexylamine, or with

procaine, dibenzylpiperidine, N-benzyl- β -phenethylamine, dehydroabietylamine, N,N'-bisdehydroabietylamine, glucamine, N-methylglucamine or bases of the pyridine type such as pyridine, collidine, quinine or quinoline.

Suitable solvates are pharmaceutically acceptable solvates.

5 Suitable pharmaceutically acceptable solvates include hydrates.

The term 'alkyl' or (C₁₋₆)alkyl (unless specified to the contrary) when used alone or when forming part of other groups (such as the 'alkoxy' group) includes straight- or branched-chain alkyl groups containing 1 to 6 carbon atoms, examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl group.

10 The term 'alkenyl' or (C₁₋₆)alkenyl (unless specified to the contrary) when used alone or when forming part of other groups includes straight- or branched-unsaturated carbon chains including at least one double C=C bond and containing 2-6 carbon atoms.

The term 'carbocyclic' refers to cycloalkyl and aryl rings.

15 The term 'cycloalkyl' includes groups having 3 to 7 ring carbon atoms.

Suitable substituents for any (C₁₋₆)alkyl, (C₁₋₆)alkenyl, or (C₃₋₇)cycloalkyl group include up to three substituents selected from the group consisting of hydroxy, halogen, nitro, cyano, carboxy, amino, mono- and di-(C₁₋₆)alkylamino, carboxamido, sulphonamido, (C₁₋₆)alkoxycarbonyl, trifluoromethyl, acyloxy, 20 aryl, heterocycle, and (C₃₋₇)cycloalkyl.

The term 'aryl' includes phenyl and naphthyl, preferably phenyl which, unless specified to the contrary optionally comprise up to five, preferably up to three substituents selected from halogen, alkyl, phenyl, alkoxy, haloalkyl, hydroxyalkyl, hydroxy, amino, nitro, cyano, carboxy, alkoxycarbonyl, alkoxycarbonylalkyl, 25 alkylcarbonyloxy, or alkylcarbonyl groups.

The term 'aromatic heterocyclic group' includes groups comprising aromatic heterocyclic rings containing from 5 to 12 ring atoms, suitably 5 or 6, and comprising up to four hetero-atoms in the or each ring selected from S, O or N.

30 Composite terms such as 'alkylcarboxy', 'cycloalkylalkyl' and so forth refer to components of a compound which include two interlinked groups, with the group named latterly in the term being the linking group, so that 'alkylcarboxy' means (alkyl)-COO- whilst 'cycloalkylalkyl' means (cycloalkyl)-(alkyl)-.


Unless specified to the contrary, suitable substituents for any heterocyclic group includes up to 4 substituents selected from the group consisting of: alkyl, alkoxy, aryl and halogen or any two substituents on adjacent carbon atoms, together with the carbon atoms to which they are attached, may form an aryl group,
 5 preferably a benzene ring, and wherein the carbon atoms of the aryl group represented by the said two substituents may themselves be substituted or unsubstituted.

When used herein the term "halogen" refers to fluorine, chlorine, bromine and iodine, preferably fluorine, chlorine or bromine.


10 When used herein the term "acyl" includes residues of acids, in particular a residue of a carboxylic acid such as an alkyl- or aryl- carbonyl group.

Certain reagents are abbreviated herein. DCC refers to dicyclohexylcarbodiimide, DMAP refers to dimethylaminopyridine, DIEA refers to diisopropylethyl amine, EDC refers to 1-(3-dimethylaminopropyl)-3-
 15 ethylcarbodiimide, hydrochloride. HOBt refers to 1-hydroxybenzotriazole, THF refers to tetrahydrofuran, DIEA refers to diisopropylethylamine, DEAD refers to diethyl azodicarboxylate, PPh₃ refers to triphenylphosphine, DIAD refers to diisopropyl azodicarboxylate, DME refers to dimethoxyethane, DMF refers to dimethylformamide, NBS refers to N-bromosuccinimide, Pd/C refers to a palladium
 20 on carbon catalyst, PPA refers to polyphosphoric acid, DPPA refers to diphenylphosphoryl azide, BOP refers to benzotriazol-1-yloxy-tris(dimethyl-amino)phosphonium hexafluorophosphate, HF refers to hydrofluoric acid, TEA refers to triethylamine, TFA refers to trifluoroacetic acid, PCC refers to pyridinium chlorochromate.


,25 The invention also provides in one aspect a process for the preparation of a compound of formula (I), or a salt thereof and/or a solvate thereof, which process comprises reacting a compound of formula (II) or an active derivative thereof:



wherein R'₄, R'₅, R'₆ and X' are R₄, R₅, R₆ and X respectively as
 hereinbefore defined in relation to formula (I) or (Ib), or a group convertible to R₄,
 5 R₅, R₆ and X respectively; with a compound of formula (III):



wherein R'₁ and R'₂ are R₁ and R₂ as defined for formula (I) or a group or
 10 atom convertible to R₁ and R₂ respectively; to form a compound of formula (Ic):



wherein R'₁, R'₂, X', R'₄, R'₅ and R'₆ are as defined above, and thereafter carrying
 out one or more of the following optional steps:

- 15 (i) converting any one of R'₁, R'₂, X', R'₄, R'₅ and R'₆ to R₁, R₂, X, R₄, R₅
 and R₆ respectively as required, to obtain a compound of formula (I);
 - (ii) converting a compound of formula (I) into another compound of formula (I);
 and
 - (iii) preparing a salt of the compound of formula (I) and/or a solvate thereof.
- 20 Suitable groups convertible into other groups include protected forms of said
 groups.

Suitably R'₁, R'₂, X', R'₄, R'₅ and R'₆ each represents R₁, R₂, X, R₄, R₅
 and R₆ respectively or a protected form thereof.

It is favoured if the compound of formula (II) is present as an active derivative.

A suitable active derivative of a compound of formula (II) is a transient activated form of the compound of formula (II) or a derivative wherein the carboxy group of the compound of formula (II) has been replaced by a different group or atom, for example by an acyl halide, preferably a chloride, or an acylazide or a carboxylic acid anhydride.

Other suitable active derivatives include: a mixed anhydride formed between the carboxyl moiety of the compound of formula (II) and an alkyl chloroformate; an activated ester, such as a cyanomethyl ester, thiophenyl ester, p-nitrophenyl ester, p-nitrothiophenyl ester, 2,4,6-trichlorophenyl ester, pentachlorophenyl ester, pentafluorophenyl ester, N-hydroxy-phthalimido ester, N-hydroxypiperidine ester, N-hydroxysuccinimide ester, N-hydroxy benzotriazole ester; alternatively, the carboxy group of the compound of formula (II) may be activated using a carbodiimide or N,N'-carbonyldiimidazole.

The reaction between the compound of formula (II) or the active derivative thereof and the compound of formula (III) is carried out under the appropriate conventional conditions for the particular compounds chosen. Generally, when the compound of formula (II) is present as an active derivative the reaction is carried out using the same solvent and conditions as used to prepare the active derivative, preferably the active derivative is prepared *in situ* prior to forming the compound of formula (Ic) and thereafter the compound of formula (I) or a salt thereof and/or a solvate thereof is prepared.

For example, the reaction between an active derivative of the compound of formula (II) and the compound of formula (III) may be carried out:

- (a) by first preparing an acid chloride and then coupling said chloride with the compound of formula (III) in the presence of an inorganic or organic base in a suitable aprotic solvent such as dimethylformamide (DMF) at a temperature in a range from -70 to 50°C (preferably in a range from -10 to 20°C); or
- (b) by treating the compound of formula (II) with a compound of formula (III) in the presence of a suitable condensing agent, such as for example N,N'-carbonyl diimidazole (CDI) or a carbodiimide such as dicyclohexylcarbodiimide

A preferred reaction is set out in Scheme 1 shown below:

In the case in which the corresponding alkyl (such as methyl or ethyl) ester of compound (II) is utilised, an hydrolysis to compound (II) is required before conversion to compound (Ic) in Scheme 1. Such hydrolysis can be carried out under acidic conditions, such 10-36% hydrochloric acid at a temperature in the range between 30 and 100 °C.

Accordingly, in a further aspect the invention provides a process for preparing a compound of formula (I), or a salt thereof and/or a solvate thereof, which process comprises converting a compound of the above defined formula (Ic)

wherein at least one of R'₁, R'₂, X', R'₄, R'₅ and R'₆ is not R₁, R₂, X, R₄, R₅ or R₆ respectively, thereby to provide a compound of formula (I); and thereafter, as required, carrying out one or more of the following optional steps:

- (i) converting a compound of formula (I) into another compound of formula (I);
5 and
(ii) preparing a salt of the compound of formula (I) and/or a solvate thereof.


Suitably, in the compound of formula (Ic) the variables R'₁, R'₂, X', R'₄, R'₅ and R'₆ are R₁, R₂, X, R₄, R₅ and R₆ respectively or they are protected forms thereof.

- 10 The above mentioned conversions, protections and deprotections are carried out using the appropriate conventional reagents and conditions and are further discussed below.

A chiral compound of formula (III) wherein R₂ is a C₅ or C₇ cycloalkyl group, R₃ is methyl and R₁ is H are described in J. Org. Chem. (1996), 61 (12),
15 4130-4135. A chiral compound of formula (III) wherein R₂ is phenyl, R₃ is isopropyl and R₁ is H is a known compound described in for example Tetrahedron Lett. (1994), 35(22), 3745-6.


The compounds of formula (III) are known commercially available compounds or they can be prepared from known compounds by known methods, or
20 methods analogous to those used to prepare known compounds, for example the methods described in Liebigs Ann. der Chemie, (1936), 523, 199.

In some embodiments of the invention, a compound of formula (II) or the corresponding alkyl (such as methyl or ethyl) ester is prepared by reacting a compound of formula (IV) or the corresponding alkyl (such as methyl or ethyl)
25 ester:



(IV)

wherein R'₄, R'₅ and R'₆ are as defined above and L₁ represents a halogen atom such as a bromine atom, with a compound of formula (V):




(V)

wherein R₃ and R₇ are as defined in relation to formula (I) or a protected form thereof.

Suitably, reaction between the compounds of formulae (IV) or the corresponding alkyl (such as methyl or ethyl) ester and (V) is carried out under conventional amination conditions, for example when L₁ is a bromine atom then the reaction is conveniently carried out in an aprotic solvent, such as tetrahydrofuran or dimethylformamide at any temperature providing a suitable rate of formation of the required product, usually at ambient temperature; preferably the reaction is carried out in the presence of triethylamine (TEA) or K₂CO₃.

The compounds of formula (V) are known, commercially available compounds or they can be prepared using methods analogous to those used to prepare known compounds; for example the methods described in the Chemistry of the Amino Group, Patai (Ed.), Interscience, New York 1968; Advanced Organic Chemistry, March J, John Wiley & Sons, New York, 1992; J. Heterocyclic Chem. (1990), 27, 1559; Synthesis (1975), 135, Bioorg. Med. Chem. Lett. (1997), 7, 555, or Protective Groups in Organic Synthesis (second edition), Wiley Interscience, (1991) or other methods mentioned herein.

A compound of formula (IV) or the corresponding alkyl (such as methyl or ethyl) ester may be prepared by appropriate halogenation of a compound of formula (VI) or the corresponding alkyl (such as methyl or ethyl) ester:




wherein R'₄, R'₅ and R'₆ are as defined above in relation to formula (II).

Suitable halogenation reagents are conventional reagents depending upon the nature of the halogen atom required, for example when L₁ is bromine a preferred
 5 halogenation reagent is N-bromosuccinimide (NBS).

The halogenation of the compound of formula (VI) or the corresponding alkyl (such as methyl or ethyl) ester is suitably carried out under conventional conditions, for example bromination is carried out by treatment with NBS in an inert solvent, such as carbon tetrachloride CCl₄, or 1,2-dichloroethane or CH₃CN, at any
 10 temperature providing a suitable rate of formation of the required product, suitably at an elevated temperature such as a temperature in the range of 60°C to 100°C, for example 80°C; preferably the reaction is carried out in the presence of a catalytic amount of benzoyl peroxide.

A compound of formula (VI) is conveniently prepared by reacting a
 15 compound of formula (VII):



wherein R'₅ and R'₆ are as defined in relation to formula (II), with a compound of
 20 formula (XIII):



wherein R'₄ is as defined in relation to formula (II).


25 The reaction between the compounds of formula (VII) and (XIII) is conveniently carried out using Pfitzinger reaction conditions (see for example J.

Prakt. Chem. 33, 100 (1886), J. Prakt. Chem. 38, 582 (1888), J. Chem. Soc. 106 (1948) and Chem. Rev. 35, 152 (1944)). For example in an alkanolic solvent such as ethanol, at any temperature providing a suitable rate of formation of the required product, but generally at an elevated temperature, such as the reflux temperature of the solvent, and preferably in the presence of a base such as potassium hydroxide or potassium tert-butoxide. The Pfitzinger reaction may also be carried out in presence of an acid, such as acetic acid or hydrochloric acid, at a temperature providing a suitable rate of formation of the required product, but generally at an elevated temperature, as described in J. Med. Chem. 38, 906 (1995).

10 The compounds of formula (VII) are known compounds or they are prepared according to methods used to prepare known compounds for example those disclosed in J. Org. Chem. 21, 171 (1955); J. Org. Chem. 21, 169 (1955).


Alternatively a compound of formula (VI) may be conveniently prepared by reacting a compound of formula (XIV)

15



wherein R'_5 and R'_6 are as defined in relation to formula (II), with a compound of formula (XV):

20




wherein R'_4 is as defined in relation to formula (II) in presence of oxobutyric acid.


25 The reaction between the compounds of formula (XIV) and (XV) is conveniently carried out using Doebner reaction conditions (see for example Chem. Ber. 29, 352 (1894); Chem. Revs. 35, 153, (1944); J. Chem. Soc. B, 1969, 805), for example in an alcoholic solvent such as ethanol, at any temperature providing a suitable rate of formation of the required product, but generally at an elevated temperature, such as the reflux temperature of the solvent.

The compounds of formula (XIV) and (XV) are known compounds or they are prepared according to methods used to prepare known compounds for example as described in *Vogel's Textbook of Practical Organic Chemistry*.


In some alternative embodiments of the invention, a compound of formula (II) is prepared by reacting a compound of formula (VII) as defined above with a compound of formula (VIII):



wherein R_4' is as defined in relation to formula (II), and T_5 is a group




where Y is a protecting group such as a benzyl group, particularly a protecting group which is stable in basic conditions such as a tertbutoxycarbonyl group; and thereafter as required removing any protecting group, for example by dehydrogenation, and/or converting any T_5 group to:



The reaction between the compounds of formula (VII) and (VIII) is conveniently carried out using Pfitzinger reaction conditions (see for example J. Prakt. Chem. 33, 100 (1886), J. Prakt. Chem. 38, 582 (1888), J. Chem. Soc. 106 (1948) and Chem. Rev. 35, 152 (1944)), for example in an alkanolic solvent such as ethanol, at any temperature providing a suitable rate of formation of the required product, but generally at an elevated temperature, such as the reflux temperature of

the solvent, and preferably in the presence of a base such as potassium hydroxide or potassium tert-butoxide.


Protected forms of,



5

will vary according to the particular nature of the group being protected but will be chosen in accordance with normal chemical practice.

Groups convertible to,




10

include groups dictated by conventional chemical practice to be required and to be appropriate, depending upon the specific nature of the group under consideration.


15

Suitable deprotection methods for deprotecting protected forms of




and conversion methods for converting T5 to,

20




will be those used conventionally in the art depending upon the particular groups under consideration with reference to standard texts such as Greene, T.W. and Wuts, P.G.M. Protective Groups in Organic Synthesis, John Wiley & Sons Inc. New York, 1991 (Second Edt.) or in Kocienski, P.J. Protecting groups. George Thieme Verlag, New York, 1994 and Chemistry of the Amino Group, Patai (Ed.), Interscience, New York 1968; or Advanced Organic Chemistry, March J, John Wiley & Sons, New York, 1992.

A compound of formula (VIII) is prepared from a compound of formula (IX):



wherein R_5' is as defined in relation to formula (II), by first halogenating, preferably brominating, or mesylating the compound of formula (IX) and thereafter reacting the halogenation or mesylation product so formed with a compound capable of forming a group T_5 so as to provide the required compound of formula (VII).

When T_5 is a group,




a compound capable of forming a group T_5 is a compound of the above defined formula (V).

The halogenation of the compound of formula (IX) is suitably carried out using a conventional halogenation reagent. Mesylation is conveniently carried out using mesyl chloride in an inert solvent such as methylene dichloride, at a temperature below room temperature, such as 0°C , preferably in the presence of triethylamine.

The reaction conditions between the compound of formula (IX) and the compound capable of forming a group T_5 will be those conventional conditions

dictated by the specific nature of the reactants, for example when the T₅ required is a group,



5


and the required compound capable of forming a group T₅ is a compound of the above defined formula (V), then the reaction between the halogenation or mesylation product of the compound of formula (IX) and the compound of formula (V) is carried out under analogous conditions to those described for the reaction between the compounds of formulae (IV) and (V).

10

Other compounds capable of forming a group T₅ will depend upon the particular nature of T₅, but will be those appropriate compounds dictated by conventional chemical practice with reference to standard texts such as Chemistry of the Amino Group, Patai (Ed.), Interscience, New York 1968; and Advanced Organic Chemistry, March J, John Wiley & Sons, New York, 1992.

15

A compound of formula (IX) may be prepared by reacting a compound of formula (X):



wherein a is as defined in relation to formula (VIII), with a lithium salt of formula (XI):

20



wherein R'₅ is as defined in relation to formula (II).


The reaction between the compounds of formulae (X) and (XI) can be carried out in an aprotic solvent, such as diethyl-ether at any temperature providing a suitable rate of formation of the required product, usually at a low temperature such as in the range of -10°C to -30°C, for example -20°C.

25

The compounds of formula (VII) are known compounds or they are prepared according to methods used to prepare known compounds for example those disclosed in *J. Org. Chem.* 21, 171 (1955); *J. Org. Chem.* 21, 169 (1955).

5 The compounds of formula (X) and (XI) are known compounds or they are prepared according to methods used to prepare known compounds for example those disclosed by Krow G. R. in *Organic Reactions*, Vol 43, page 251, John Wiley & Sons Inc.1994 (for the compounds of formula (X)) and *Organometallics in Synthesis*, Schlosser M.(Ed), John Wiley & Sons Inc.1994 (for the compounds of formula (XI)).

10 In another aspect, the present invention provides a process for the preparation of a compound of formula (I), or a salt thereof and/or a solvate thereof, which process comprises reacting a compound of formula (XVI):



15 wherein each of R'1, R'2, R'4, R'5, and R'6 is respectively R1, R2, R4, R5, or R6 as defined above or a group convertible to R1, R2, R4, R5, or R6 respectively as defined above providing R'2 is not aromatic in character, and L1 represents a halogen atom such as a bromine atom, with a compound of formula (V) or a
20 protected form thereof or a group convertible thereto; and thereafter carrying out one or more of the following optional steps:

- (i) converting any one of R'1, R'2, R'3, R'4, R'5, and R'6 to R1, R2, R3, R4, R5, and R6 respectively as required, to obtain a compound of formula (I);
- (ii) converting a compound of formula (I) into another compound of formula (I);
- 25 and
- (iii) preparing a salt of the compound of formula (I) and/or a solvate thereof.

Protected forms of compounds of formula (V) will vary according to the particular nature of the group being protected but will be chosen in accordance with normal chemical practice.

5 Groups convertible to R_3 include groups dictated by conventional chemical practice to be required and to be appropriate, depending upon the specific nature of the R_3 under consideration.

Suitable deprotection methods for deprotecting protected forms of R_3 and conversion methods for converting R'_3 to R_3 will be those used conventionally in the art depending upon the particular groups under consideration with reference to
10 standard texts such as Greene, T.W. and Wuts, P.G.M. Protective Groups in Organic Synthesis, John Wiley & Sons Inc. New York, 1991 (Second Edt.) or in Kocienski, P.J. Protecting groups. George Thieme Verlag, New York, 1994 and Chemistry of the Amino Group, Patai (Ed.), Interscience, New York 1968; or Advanced Organic Chemistry, March J, John Wiley & Sons, New York, 1992.

15 Suitable groups convertible into other groups include protected forms of said groups.

Suitably R'_1 , R'_2 , R'_3 , R'_4 , R'_5 , and R'_6 each represents R_1 , R_2 , R_3 , R_4 , R_5 , and R_6 respectively or a protected form thereof.


Suitable deprotection methods for deprotecting protected forms of R_1 , R_2 ,
20 R_3 , R_4 , R_5 , and R_6 and conversion methods for converting R'_1 , R'_2 , R'_3 , R'_4 , R'_5 , and R'_6 to R_1 , R_2 , R_3 , R_4 , R_5 , and R_6 respectively will be those used conventionally in the art depending upon the particular groups under consideration with reference to standard texts such as Greene, T.W. and Wuts, P.G.M. Protective Groups in Organic Synthesis, John Wiley & Sons Inc. New York, 1991 (Second
25 Edt.) or in Kocienski, P.J. Protecting groups. George Thieme Verlag, New York, 1994 and Chemistry of the Amino Group, Patai (Ed.), Interscience, New York 1968; or Advanced Organic Chemistry, March J, John Wiley & Sons, New York, 1992.

Suitably, reaction between the compounds of formulae (XVI) and (XVII) is
30 carried out under conventional amination conditions, for example when L_1 is a bromine atom then the reaction is conveniently carried out in an aprotic solvent, such as tetrahydrofuran or dimethylformamide or acetonitrile at any temperature

providing a suitable rate of formation of the required product, usually at ambient temperature; preferably the reaction is carried out in the presence of triethylamine (TEA), sodium hydride or K_2CO_3 .

The compounds of formula (XVII) are known, commercially available
5 compounds or they can be prepared using methods analogous to those used to prepare known compounds; for example the methods described in the Chemistry of the Amino Group, Patai (Ed.), Interscience, New York 1968; Advanced Organic Chemistry, March J, John Wiley & Sons, New York, 1992 ; J. Heterocyclic Chem. (1990), 27, 1559; Synthesis (1975), 135, Bioorg. Med. Chem. Lett. (1997), 7, 555,
10 or Protective Groups in Organic Synthesis (second edition), Wiley Interscience, (1991) or other methods mentioned herein.

A compound of formula (XVI) is prepared by appropriate halogenation of a compound of formula (XVIII):



(XVIII)

15 wherein R'1, R'2, R'4, R'5, and R'6 are as defined above in relation to formula (XVI).

Suitable halogenation reagents are conventional reagents depending upon the nature of the halogen atom required, for example when L1 is bromine a preferred
20 halogenation reagent is N-bromosuccinimide (NBS).

The halogenation of the compound of formula (XVIII) is carried out under conventional conditions, for example bromination is carried out by treatment with NBS in an inert solvent, such as carbon tetrachloride CCl_4 , or 1,2-dichloroethane or CH_3CN , at any temperature providing a suitable rate of formation of the required
25 product, suitably at an elevated temperature such as a temperature in the range of $60^\circ C$ to $100^\circ C$, for example $80^\circ C$; preferably the reaction is carried out in the presence of a catalytic amount of benzoyl peroxide.

Suitably, the compound of formula (XVIII) may be prepared by reacting a compound of formula (VI) as defined above or an active derivative thereof with a compound of formula (III) as defined above wherein R'₂ is not aromatic in character.

5 It is favoured if the compound of formula (VI) is present in the reaction mix as an active derivative, as hereinbefore described.

The reaction between the compound of formula (VI) or the active derivative thereof and the compound of formula (III) is carried out under the appropriate conventional conditions for the particular compounds chosen. Generally, when the
10 compound of formula (VI) is present as an active derivative the reaction is carried out using the same solvent and conditions as used to prepare the active derivative, preferably the active derivative is prepared *in situ* prior to forming the compound of formula (XVIII).


For example, the reaction between an active derivative of the compound of
15 formula (VI) and the compound of formula (III) may be carried out:

(a) by first preparing an acid chloride and then coupling said chloride with the compound of formula (III) in the presence of an inorganic or organic base in a suitable aprotic solvent such as methylene dichloride or tetrahydrofuran at a temperature in a range from -70 to 50°C (preferably in a range from 20°C to reflux
20 temperature); or

(b) by treating the compound of formula (VI) with a compound of formula (III) in the presence of a suitable condensing agent, such as for example N,N'-carbonyl diimidazole (CDI) or a carbodiimide such as dicyclohexylcarbodiimide (DCC) or N-dimethylaminopropyl-N'-ethylcarbodiimide, preferably in the presence
25 of N-hydroxybenzotriazole (HOBt) to maximise yields and avoid racemization processes (see *Synthesis*, 453, 1972), or O-benzotriazol-1-yl-N,N,N',N'-tetramethyluroniumhexafluorophosphate (HBTU), in an aprotic solvent, such as a mixture of acetonitrile (MeCN) and tetrahydrofuran (THF), for example a mixture in a volume ratio of from 1:9 to 7:3 (MeCN:THF), at any temperature providing a
30 suitable rate of formation of the required product, such as a temperature in the range of from -70 to 50°C, preferably in a range of from -10 to 25°C, for example at 0°C.


A preferred reaction is set out in Scheme 2 shown below:

Scheme 2




5 In the case in which the corresponding alkyl (such as methyl or ethyl) ester of compounds (VI) is utilised, a hydrolysis is required before conversion to compound (XVIII) in Scheme 2. Such hydrolysis can be carried out under acidic conditions, such 10-36% hydrochloric acid at a temperature in the range between 30 and 100 °C.

10 As hereinbefore mentioned, the compounds of formula (I) may exist in more than one stereoisomeric form - and the process of the invention may produce racemates as well as enantiomerically pure forms. Accordingly, a pure enantiomer of a compound of formula (I) can be obtained by reacting a compound of the above defined formula (II) with an appropriate enantiomerically pure primary amine of
 15 formula (IIIa) or (IIIc):




(IIIa)




(IIIc)

wherein R'₁, and R'₂ are as defined above, to obtain a compound of formula
 20 (I'a) or (I'c):




(I'a)




(I'c)

wherein R'_1 , R'_2 , X' , R'_4 , R'_5 , and R'_6 are as defined above.

Compounds of formula (I'a) or (I'c) may subsequently be converted to
 5 compounds of formula (Ia) or (Ic) by the methods of conversion mentioned before:



(Ia)



(Ic)

10 wherein R_1 , R_2 , X , R_4 , R_5 , and R_6 are as defined above.

An alternative method for separating optical isomers is to use conventional, fractional separation methods in particular fractional crystallization methods. Thus, a pure enantiomer of a compound of formula (I) is obtained by fractional crystallisation of a diastereomeric salt formed by reaction of the racemic compound
 15 of formula (I) with an optically active strong acid resolving agent, such as camphosulphonic acid, tartaric acid, O,O'-di-p-toluoyltartaric acid or mandelic acid, in an appropriate alcoholic solvent, such as ethanol or methanol, or in a ketonic solvent, such as acetone. The salt formation process should be conducted at a temperature between 20°C and 80°C, preferably at 50°C.

20 A suitable conversion of one compound of formula (I) into a further compound of formula (I) involves converting one group X into another group X by for example:

- (i) converting a ketal into a ketone, by such as mild acidic hydrolysis, using for example dilute hydrochloric acid;
- (ii) reducing a ketone to a hydroxy group by use of a borohydride reducing agent;
- (iii) converting a carboxylic ester group into a carboxyl group using basic
5 hydrolysis; and/or
- (iv) reducing a carboxylic ester group to a hydroxymethyl group, by use of a borohydride reducing agent.

As indicated above, where necessary, the conversion of any group R'_1 , R'_2 , X' , R'_4 , R'_5 , and R'_6 into R_1 , R_2 , X , R_4 , R_5 , and R_6 which as stated above are
10 usually protected forms of R_1 , R_2 , X , R_4 , R_5 , or R_6 may be carried out using appropriate conventional conditions such as the appropriate deprotection procedure.


It will be appreciated that in any of the above mentioned reactions any reactive group in the substrate molecule may be protected and deprotected according to conventional chemical practice, for example as described by Greene, T.W. and
15 Wuts, P.G.M. *Protective Groups in Organic Synthesis*, John Wiley & Sons Inc. New York, 1991 (Second Edt.) or in Kocienski, P.J. *Protecting groups*. George Thieme Verlag, New York, 1994.

Suitable protecting groups in any of the above mentioned reactions are those used conventionally in the art. Thus, for example suitable hydroxy protecting
20 groups include benzyl or trialkylsilyl groups.

The methods of formation and removal of such protecting groups are those conventional methods appropriate to the molecule being protected. Thus for example a benzyloxy group may be prepared by treatment of the appropriate compound with a benzyl halide, such as benzyl bromide, and thereafter, if required,
25 the benzyl group may be conveniently removed using catalytic hydrogenation or a mild ether cleavage reagent such as trimethylsilyl iodide or boron tribromide.

The compounds of the present invention were prepared by the methods illustrated in Schemes III and IV.

Scheme III




Reagents and Conditions: a) KOH, EtOH; b) i) Oxalyl chloride, DMF (cat.)
 5 CH₂Cl₂; ii) (S)-Cyclohexylethylamine, triethylamine, CH₂Cl₂; c) NBS, dibenzoyl
 peroxide, CCl₄; d) 2-oxo-piperazine, N,N-diisopropylethylamine, CH₃CN; e) NaH,
 Bromoacetic acid ethyl ester, DMF, 18hrs., then, LiOH, MeOH/water; f)
 Dimethylamine, HBTU, 4-methylmorpholine, DMF.

Thus, reaction of 1-(2-thienyl)-1-propanone with isatin under basic
 10 conditions yields the desired carboxylic acid **III-3**. Conversion to the acid chloride
 followed by reaction with R-(-)-1-cyclohexylethylamine produces amide **III-4**. This
 in turn is converted to 3-(3-oxo-piperazin-1-ylmethyl)-2-thiophen-2-yl-quinoline-4-
 carboxylic acid ((S)-1-cyclohexyl-ethyl)-amide (**III-6**) (WO0244165) via the two
 step procedure of free radical bromination followed by S_N2 displacement with

piperazin-2-one. Reaction of intermediate **III-6** with sodium hydride followed by bromoacetic acid ethylester in DMF produces the intermediate ester. This is subsequently hydrolyzed to the acid in the same pot via treatment with lithium hydroxide in methanol/water (1:1) to produce acid **III-7**. Coupling of this acid with dimethylamine is accomplished with HBTU and 4-methylmorpholine in DMF yielding the desired amide **III-8**.

Alternatively, compounds of formula (I) may be prepared in a fashion analogous to that depicted in Scheme IV.

Scheme IV



10

a) NaH, 3-oxo-piperazine-1-carboxylic acid tert-butylester, DMF/DMSO (5/1), 0°C; b) HCl, dioxane; c) N,N-diisopropyl ethylamine, bromoacetic acid ethylester; d) LiOH, EtOH, e) Morpholine, HBTU, 4-methylmorpholine, DMF.

Thus, S_N2 displacement of the quinolinyl bromide with 3-oxo-piperazine-1-carboxylic acid tert-butyl ester under basic conditions affords BOC carbamate IV-5. Removal of the BOC protecting group under acidic conditions followed by reaction of the product amine with bromoacetic acid ethylester in the presence of Hunig's
5 base affords ester IV-7. The ester may be hydrolyzed under basic conditions followed by coupling of the product acid with morpholine in the presence of HBTU and 4-methylmorpholine yielding the desired amide IV-9.

As indicated above, the compounds of formula (I) have useful pharmaceutical properties.

10 Accordingly the present invention also provides a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, for use as an active therapeutic substance.

In particular, the present invention also provides a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, for the treatment or
15 prophylaxis of the Primary and Secondary Conditions.

The present invention further provides a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier.

The present invention also provides the use of a compound of formula (I), or
20 a pharmaceutically acceptable salt or solvate thereof, in the manufacture of a medicament for the treatment of the Primary and Secondary Conditions.

As mentioned above the Primary conditions include respiratory diseases, such as chronic obstructive pulmonary disease (COPD), asthma, airway hyperreactivity, cough; inflammatory diseases such as inflammatory bowel disease,
25 psoriasis, fibrositis, osteoarthritis, rheumatoid arthritis and inflammatory pain; neurogenic inflammation or peripheral neuropathy, allergies such as eczema and rhinitis; ophthalmic diseases such as ocular inflammation, conjunctivitis, vernal conjunctivitis and the like; cutaneous diseases, skin disorders and itch, such as cutaneous wheal and flare, contact dermatitis, atopic dermatitis, urticaria and other
30 eczematoid dermatitis; adverse immunological reactions such as rejection of transplanted tissues and disorders related to immune enhancement or suppression such as systemic lupus erythematosus; gastrointestinal (GI) disorders and diseases

of the GI tract such as disorders associated with the neuronal control of viscera such as ulcerative colitis, Crohn's disease, irritable bowel syndrome (IBS), gastro-exophageous reflex disease (GERD); urinary incontinence and disorders of the bladder function; renal disorders.

5 As mentioned above, the Secondary conditions disorders of the central nervous system such as anxiety, depression, psychosis and schizophrenia; neurodegenerative disorders such as AIDS related dementia, senile dementia of the Alzheimer type, Alzheimer's disease, Down's syndrome, Huntington's disease, Parkinson's disease, movement disorders and convulsive disorders (for example
10 epilepsy); demyelinating diseases such as multiple sclerosis and amyotrophic lateral sclerosis and other neuropathological disorders such as diabetic neuropathy, AIDS related neuropathy, chemotherapy-induced neuropathy and neuralgia; addiction disorders such as alcoholism; stress related somatic disorders; reflex sympathetic dystrophy such as shoulder/hand syndrome; dysthymic disorders; eating disorders
15 (such as food intake disease); fibrosing and collagen diseases such as scleroderma and eosinophilic fasciitis; disorders of the blood flow caused by vasodilation and vasospastic diseases such as angina, migraine and Reynaud's disease and pain or nociception, for example, that is attributable to or associated with any of the foregoing conditions especially the transmission of pain in migraine.

20 Such a medicament, and a composition of this invention, may be prepared by admixture of a compound of the invention with an appropriate carrier. It may contain a diluent, binder, filler, disintegrant, flavouring agent, colouring agent, lubricant or preservative in conventional manner.

25 These conventional excipients may be employed for example as in the preparation of compositions of known agents for treating the conditions.

Preferably, a pharmaceutical composition of the invention is in unit dosage form and in a form adapted for use in the medical or veterinarial fields. For example, such preparations may be in a pack form accompanied by written or printed instructions for use as an agent in the treatment of the conditions.

30 The suitable dosage range for the compounds of the invention depends on the compound to be employed and on the condition of the patient. It will also depend,

inter alia, upon the relation of potency to absorbability and the frequency and route of administration.

The compound or composition of the invention may be formulated for administration by any route, and is preferably in unit dosage form or in a form that a human patient may administer to himself in a single dosage. Advantageously, the composition is suitable for oral, rectal, topical, parenteral, intravenous or intramuscular administration. Preparations may be designed to give slow release of the active ingredient.

Compositions may, for example, be in the form of tablets, capsules, sachets, vials, powders, granules, lozenges, reconstitutable powders, or liquid preparations, for example solutions or suspensions, or suppositories.

The compositions, for example those suitable for oral administration, may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrrolidone; fillers, for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tableting lubricants, for example magnesium stearate; disintegrants, for example starch, polyvinyl-pyrrolidone, sodium starch glycollate or microcrystalline cellulose; or pharmaceutically acceptable setting agents such as sodium lauryl sulphate.

Solid compositions may be obtained by conventional methods of blending, filling, tableting or the like. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers. When the composition is in the form of a tablet, powder, or lozenge, any carrier suitable for formulating solid pharmaceutical compositions may be used, examples being magnesium stearate, starch, glucose, lactose, sucrose, rice flour and chalk. Tablets may be coated according to methods well known in normal pharmaceutical practice, in particular with an enteric coating. The composition may also be in the form of an ingestible capsule, for example of gelatin containing the compound, if desired with a carrier or other excipients.

Compositions for oral administration as liquids may be in the form of, for example, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid compositions may contain conventional additives such as suspending agents, for

example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminium stearate gel, hydrogenated edible fats; emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; aqueous or non-aqueous vehicles, which include edible oils, for example almond oil,
 5 fractionated coconut oil, oily esters, for example esters of glycerine, or propylene glycol, or ethyl alcohol, glycerine, water or normal saline; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid; and if desired conventional flavouring or colouring agents.

The compounds of this invention may also be administered by a non-oral
 10 route. In accordance with routine pharmaceutical procedure, the compositions may be formulated, for example for rectal administration as a suppository. They may also be formulated for presentation in an injectable form in an aqueous or non-aqueous solution, suspension or emulsion in a pharmaceutically acceptable liquid, e.g. sterile pyrogen-free water or a parenterally acceptable oil or a mixture of
 15 liquids. The liquid may contain bacteriostatic agents, anti-oxidants or other preservatives, buffers or solutes to render the solution isotonic with the blood, thickening agents, suspending agents or other pharmaceutically acceptable additives. Such forms will be presented in unit dose form such as ampoules or disposable injection devices or in multi-dose forms such as a bottle from which the appropriate
 20 dose may be withdrawn or a solid form or concentrate which can be used to prepare an injectable formulation.

The compounds of this invention may also be administered by inhalation, via the nasal or oral routes. Such administration can be carried out with a spray formulation comprising a compound of the invention and a suitable carrier,
 25 optionally suspended in, for example, a hydrocarbon propellant.

Preferred spray formulations comprise micronised compound particles in combination with a surfactant, solvent or a dispersing agent to prevent the sedimentation of suspended particles. Preferably, the compound particle size is from about 2 to 10 microns.

30 A further mode of administration of the compounds of the invention comprises transdermal delivery utilising a skin-patch formulation. A preferred formulation comprises a compound of the invention dispersed in a pressure sensitive

adhesive which adheres to the skin, thereby permitting the compound to diffuse from the adhesive through the skin for delivery to the patient. For a constant rate of percutaneous absorption, pressure sensitive adhesives known in the art such as natural rubber or silicone can be used.

5 As mentioned above, the effective dose of compound depends on the particular compound employed, the condition of the patient and on the frequency and route of administration. A unit dose will generally contain from 20 to 1000 mg and preferably will contain from 30 to 500 mg, in particular 50, 100, 150, 200, 250, 300, 350, 400, 450, or 500 mg. The composition may be administered once or more
10 times a day for example 2, 3 or 4 times daily, and the total daily dose for a 70 kg adult will normally be in the range 100 to 3000 mg. Alternatively the unit dose will contain from 2 to 20 mg of active ingredient and be administered in multiples, if desired, to give the preceding daily dose.

No unacceptable toxicological effects are expected with compounds of the
15 invention when administered in accordance with the invention.

The present invention also provides a method for the treatment and/or prophylaxis of the Primary and Secondary Conditions in mammals, particularly humans, which comprises administering to the mammal in need of such treatment and/or prophylaxis an effective, non-toxic pharmaceutically acceptable amount of a
20 compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof.

The activity of the compounds of the present invention, as NK₃ ligands, is determined by their ability to inhibit the binding of the radiolabelled NK₃ ligands, [¹²⁵I]-[Me-Phe⁷]-NKB or [³H]-Senktide, to guinea-pig and human NK₃ receptors (Renzetti et al, 1991, *Neuropeptide*, 18, 104-114; Buell et al, 1992, *FEBS*, 299(1),
25 90-95; Chung et al, 1994, *Biochem. Biophys. Res. Commun.*, 198(3), 967-972).

The binding assays utilized allow the determination of the concentration of the individual compound required to reduce by 50% the [¹²⁵I]-[Me-Phe⁷]-NKB and [³H]-Senktide specific binding to NK₃ receptor in equilibrium conditions (IC₅₀).

Binding assays provide for each compound tested a mean IC₅₀ value of 2-5
30 separate experiments performed in duplicate or triplicate. The most potent compounds of the present invention show IC₅₀ values in the range 10-1000 nM. The NK₃-antagonist activity of the compounds of the present invention is

determined by their ability to inhibit senktide-induced contraction of the guinea-pig ileum (Maggi et al, 1990, *Br. J. Pharmacol.*, 101, 996-1000) and rabbit isolated iris sphincter muscle (Hall et al., 1991, *Eur. J. Pharmacol.*, 199, 9-14) and human NK₃ receptors-mediated Ca⁺⁺ mobilization (Mochizuki et al, 1994, *J. Biol. Chem.*, 269, 9651-9658). Guinea-pig and rabbit *in-vitro* functional assays provide for each compound tested a mean K_B value of 3-8 separate experiments, where K_B is the concentration of the individual compound required to produce a 2-fold rightward shift in the concentration-response curve of senktide. Human receptor functional assay allows the determination of the concentration of the individual compound required to reduce by 50% (IC₅₀ values) the Ca⁺⁺ mobilization induced by the agonist NKB. In this assay, the compounds of the present invention behave as antagonists.

The activity of the compounds of the present invention, as NK-2 ligands, is determined by their ability to inhibit the binding of the radiolabelled NK-2 ligands, [¹²⁵I]-NKA or [³H]-NKA, to human NK-2 receptors (Aharony et al, 1992, *Neuropeptide*, 23, 121-130).

The binding assays utilized allow the determination of the concentration of the individual compound required to reduce by 50% the [¹²⁵I]-NKA and [³H]-NKA specific binding to NK-2 receptor in equilibrium conditions (IC₅₀).

Binding assays provide for each compound tested a mean IC₅₀ value of 2-5 separate experiments performed in duplicate or triplicate. The most potent compounds of the present invention show IC₅₀ values in the range 1-1000 nM, such as 1-100 nM. The NK-2-antagonist activity of the compounds of the present invention is determined by their ability to inhibit human NK-2 receptor-mediated Ca⁺⁺ mobilization (Mochizuki et al, 1994, *J. Biol. Chem.*, 269, 9651-9658). Human receptor functional assay allows the determination of the concentration of the individual compound required to reduce by 50% (IC₅₀ values) the Ca⁺⁺ mobilization induced by the agonist NKA. In this assay, the compounds of the present invention behave as antagonists.

The therapeutic potential of the compounds of the present invention in treating the conditions can be assessed using rodent disease models.

As stated above, the compounds of formula (I) are also considered to be useful as diagnostic tool. Accordingly, the invention includes a compound of formula (I) for use as diagnostic tools for assessing the degree to which neurokinin-2 and neurokinin-3 receptor activity (normal, overactivity or underactivity) is implicated in a patient's symptoms. Such use comprises the use of a compound of formula (I) as an antagonist of said activity, for example including but not restricted to tachykinin agonist-induced inositol phosphate turnover or electrophysiological activation, of a cell sample obtained from a patient. Comparison of such activity in the presence or absence of a compound of formula (I), will disclose the degree of NK-2 and NK-3 receptor involvement in the mediation of agonist effects in that tissue.

Descriptions and Examples

Nuclear magnetic resonance spectra were recorded at 400 MHz using a Bruker AC 400 spectrometer. CDCl_3 is deuteriochloroform, DMSO-d_6 is hexadeuteriodimethylsulfoxide, and CD_3OD is tetradeuteriomethanol. Chemical shifts are reported in parts per million (δ) downfield from the internal standard tetramethylsilane. Abbreviations for NMR data are as follows: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, dd = doublet of doublets, dt = doublet of triplets, app = apparent, br = broad. J indicates the NMR coupling constant measured in Hertz. Continuous wave infrared (IR) spectra were recorded on a Perkin-Elmer 683 infrared spectrometer, and Fourier transform infrared (FTIR) spectra were recorded on a Nicolet Impact 400 D infrared spectrometer. IR and FTIR spectra were recorded in transmission mode, and band positions are reported in inverse wavenumbers (cm^{-1}). Mass spectra were taken on either VG 70 FE, PE Syx API III, or VG ZAB HF instruments, using fast atom bombardment (FAB) or electrospray (ES) ionization techniques. Elemental analyses were obtained using a Perkin-Elmer 240C elemental analyzer. Melting points were taken on a Thomas-Hoover melting point apparatus and are uncorrected. All temperatures are reported in degrees Celsius.

Analtech Silica Gel GF and E. Merck Silica Gel 60 F-254 thin layer plates were used for thin layer chromatography. Both flash and gravity chromatography were carried out on E. Merck Kieselgel 60 (230-400 mesh) silica gel.

5 Examples

In the following synthetic examples, temperature is in degrees Centigrade (°C). Unless otherwise indicated, all of the starting materials were obtained from commercial sources. For reverse phase HPLC (unless otherwise stated), a 50 X 20 mm I. D. YMC CombiPrep ODS-A column at 20 mL/min with a 10 min gradient from 10% CH₃CN to 90% CH₃CN in H₂O was used with a 2 min hold at 90% CH₃CN in H₂O at the end of each run. Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. These Examples are given to illustrate the invention, not to limit its scope. Reference is made to the claims for what is reserved to the inventors hereunder.

Example 1

3-(4-Dimethylcarbamoylmethyl-3-oxo-piperazin-1-ylmethyl)-2-thiophen-2-yl-quinoline-4-carboxylic acid ((S)-1-cyclohexyl-ethyl)-amide

20 1a) 3-Bromomethyl-2-thiophen-2-yl-quinoline-4-carboxylic acid, (S)-(1-cyclohexylethyl)amide

Methyl-2-thiophen-2-yl-quinoline-4-carboxylic acid, (S)-(1-cyclohexyl-ethyl)amide 10 g (0.0265 mol) and N-bromosuccinimide 9.4g (0.0528 mol) were suspended in rapidly stirring carbontetrachloride (350 mL). The mixture was warmed to 80° C in a hot water bath after which time dibenzoyl peroxide (1.28 g, 0.0053 mol) was added in one portion. The mixture was heated at reflux for 30 minutes then cooled rapidly in an ice bath. The resulting suspension was filtered and the filtrate concentrated under reduced pressure. The resulting residue was taken into ethyl acetate and washed with saturated sodium bicarbonate solution, water, brine, and

dried over sodium sulfate. Removal of the solvent under reduced pressure provided the crude material which was used in the next step without further purification.

5 1b) 3-(3-oxo-piperazin-1-ylmethyl)-2-thiophen-2-yl-quinoline-4-carboxylic acid (S)-(1-cyclohexyl-ethyl)-amide

A solution of 3-Bromomethyl-2-thiophen-2-yl-quinoline-4-carboxylic acid, (S)-(1-cyclohexylethyl)amide (Example 1c), 2-oxo-piperazine (2.64 g, 26.4 mmol) and diisopropylethyl amine (9.2 mL, 52.8 mmol) was kept at room temperature
10 overnight. The solution was evaporated to dryness and the resulting residue purified by silica gel chromatography (gradient – 80 EtOAc/20 Hexanes/2 TEA to 100 EtOAc/2 TEA;). The product containing fractions were combined and concentrated and the resulting solid recrystallized from dichloroethane. The remaining impurity was removed via silica gel chromatography (gradient – 70 EtOAc/30 Hexanes/2
15 TEA to 100 EtOAc/2 TEA to give 1.8 g of pure product. MS (m/z) 477 M⁺.

1c) {4-[4-((S)-1-Cyclohexyl-ethylcarbamoyl)-2-thiophen-2-yl-quinolin-3-ylmethyl]-2-oxo-piperazin-1-yl}-acetic acid

A mixture of 3-(3-oxo-piperazin-1-ylmethyl)-2-thiophen-2-yl-quinoline-4-carboxylic acid ((S)-1-cyclohexyl-ethyl)-amide (1.5g, 3.14mmol) and sodium
20 hydride (0.19g, 7.86mmol) in 10 mL of DMF was stirred for 10 min at 0°C. Bromoacetic acid ethyl ester (0.35mL, 3.14mmol) was then added, and the resultant mixture stirred for an additional 18 hours at ambient temperature. A mixture of lithium hydroxide (100mg) in 2mL of methanol and water (1:1) was then added to
25 the reaction mixture. After stirring for 18 hours, the suspension was filtered and the filtrate concentrated to yield the crude product. Purification via reverse phase HPLC, eluting with acetonitrile/water/0.1% TFA (10/90, v/v to 90/10, v/v, over 10min), gave the desired product (1.54g, 92%). MS (m/z) 535.2 (M⁺), 1.84min.

30 1d) 3-(4-Dimethylcarbamoylmethyl-3-oxo-piperazin-1-ylmethyl)-2-thiophen-2-yl-quinoline-4-carboxylic acid ((S)-1-cyclohexyl-ethyl)-amide

To a solution of {4-[4-((S)-1-Cyclohexyl-ethylcarbamoyl)-2-thiophen-2-yl-quinolin-3-ylmethyl]-2-oxo-piperazin-1-yl}-acetic acid (Example 1c, 100 mg, 0.19mmol) in 1.0 mL of DMF, dimethylamine (0.14mL, 0.29mmol), HBTU (110mg, 0.29 mmol) and 4-methylmorpholine (63 μ L, 0.57mmol) were added. After the reaction mixture was stirred at room temperature for 18 hours, it was partitioned between ethyl acetate and water. The combined organic phase was washed with water, brine, dried over $MgSO_4$, filtered and concentrated. Purification via reverse phase HPLC, eluting with acetonitrile/water (10/90, v/v to 90/10, v/v, over 10min), gave the desired product (67mg, 63%).

10 MS (m/z) 562.0 (M^+), 1.97min.

Example 2

3-[4-(2-Morpholin-4-yl-2-oxo-ethyl)-3-oxo-piperazin-1-ylmethyl]-2-thiophen-2-yl-quinoline-4-carboxylic acid ((S)-1-cyclohexyl-ethyl)-amide

15 Following the general procedure described in Example 1d, {4-[4-((S)-1-Cyclohexyl-ethylcarbamoyl)-2-thiophen-2-yl-quinolin-3-ylmethyl]-2-oxo-piperazin-1-yl}-acetic acid (Example 1c) was coupled with morpholine to give the title compound. MS (m/z) 604.2 (M^+), 1.97min.

20 Example 3

3-[3-Oxo-4-(2-oxo-2-piperazin-1-yl-ethyl)-piperazin-1-ylmethyl]-2-thiophen-2-yl-quinoline-4-carboxylic acid ((S)-1-cyclohexyl-ethyl)-amide

Following the general procedure described in Example 1d, {4-[4-((S)-1-Cyclohexyl-ethylcarbamoyl)-2-thiophen-2-yl-quinolin-3-ylmethyl]-2-oxo-piperazin-1-yl}-acetic acid (Example 1c) was coupled with piperazine-1-carboxylic acid tert-butyl ester to give 4-(2-{4-[4-((S)-1-cyclohexyl-ethylcarbamoyl)-2-thiophen-2-yl-quinolin-3-ylmethyl]-2-oxo-piperazin-1-yl}-ethanoyl)-piperazine-1-carboxylic acid tert-butyl ester. The crude compound was dissolved in 3mL of methanol, stirred with 4N HCl in 1,4-dioxane (1 mL) for 1 hour. The mixture was concentrated to give the crude product which upon purification via Reverse phase HPLC, eluting with

acetonitrile/water (10/90, v/v to 90/10, v/v, over 10min), gave the desired product (35mg, 30%). MS (m/z) 603.6 (M^+), 1.63min.

Example 4

- 5 3-(4-Carbamoylmethyl-3-oxo-piperazin-1-ylmethyl)-2-thiophen-2-yl-quinoline-4-carboxylic acid ((S)-1-cyclohexyl-ethyl)-amide

Following the general procedure described in Example 1d, {4-[4-((S)-1-Cyclohexylethylcarbamoyl)-2-thiophen-2-yl-quinolin-3-ylmethyl]-2-oxo-piperazin-1-yl}-acetic acid (Example 1c) was coupled with ammonia to give the title compound (49%).

- 10 MS (m/z) 534.2 (M^+), 1.79min.

Example 5

- 3-{4-[2-(4-Methyl-piperazin-1-yl)-2-oxo-ethyl]-3-oxo-piperazin-1-ylmethyl}-2-thiophen-2-yl-quinoline-4-carboxylic acid ((S)-1-cyclohexyl-ethyl)-amide

- 15 Following the general procedure described in Example 1d, {4-[4-((S)-1-Cyclohexylethylcarbamoyl)-2-thiophen-2-yl-quinolin-3-ylmethyl]-2-oxo-piperazin-1-yl}-acetic acid (Example 1c) was coupled with N-methylpiperazine to give the title compound (16%). MS (m/z) 617.2 (M^+), 1.62min.

20 Example 6

- 3-[3-Oxo-4-(2-oxo-piperidin-1-yl-ethyl)-piperazin-1-ylmethyl]-2-thiophen-2-yl-quinoline-4-carboxylic acid ((S)-1-cyclohexyl-ethyl)-amide

- Following the general procedure described in Example 1d, {4-[4-((S)-1-Cyclohexylethylcarbamoyl)-2-thiophen-2-yl-quinolin-3-ylmethyl]-2-oxo-piperazin-1-yl}-acetic acid (Example 1c) was coupled with piperidine to give the title compound (63%).
- 25 MS (m/z) 602.0 (M^+), 2.19min.

Example 7

3-[3-Oxo-4-(2-oxo-pyrrolidin-1-yl-ethyl)-piperazin-1-ylmethyl]-2-thiophen-2-yl-quinoline-4-carboxylic acid ((S)-1-cyclohexyl-ethyl)-amide

Following the general procedure described in Example 1d, {4-[4-((S)-1-Cyclohexyl-ethylcarbamoyl)-2-thiophen-2-yl-quinolin-3-ylmethyl]-2-oxo-piperazin-1-yl}-acetic acid (Example 1c) was coupled with pyrrolidine to give the title compound (43%).
MS (m/z) 587.6 (M^+), 2.07min.

Example 8

3-[4-(3-Morpholin-4-yl-3-oxo-propyl)-3-oxo-piperazin-1-ylmethyl]-2-thiophen-2-yl-quinoline-4-carboxylic acid ((S)-1-cyclohexyl-ethyl)-amide

8a) 3-{4-[4-((S)-1-Cyclohexyl-ethylcarbamoyl)-2-thiophen-2-yl-quinolin-3-ylmethyl]-2-oxo-piperazin-1-yl}-propionic acid

To a solution of 3-(3-oxo-piperazin-1-ylmethyl)-2-thiophen-2-yl-quinoline-4-carboxylic acid ((S)-1-cyclohexyl-ethyl)-amide (Example 1c) (100mg, 0.21mmol) in 5mL of acetonitrile, was added potassium hydroxide (35mg, 0.63mmol), followed by ethyl acrylate (0.033mL, 0.31mmol). The mixture was stirred at room temperature for 3 days, then concentrated. The residue was acidified with 1N aqueous HCl and extracted with dichloromethane (2x). The organic phase was dried over Na_2SO_4 , and concentrated to give the crude material. This was used directly in the next step without further purification.

8b) 3-[4-(3-Morpholin-4-yl-3-oxo-propyl)-3-oxo-piperazin-1-ylmethyl]-2-thiophen-2-yl-quinoline-4-carboxylic acid ((S)-1-cyclohexyl-ethyl)-amide

Following the general procedure described in Example 1d, 3-{4-[4-((S)-1-Cyclohexyl-ethylcarbamoyl)-2-thiophen-2-yl-quinolin-3-ylmethyl]-2-oxo-piperazin-1-yl}-propionic acid (Example 8a) was coupled with morpholine to give the title compound (84%, two steps). MS (m/z) 618.4 (M^+), 1.99min.

Example 9

3-[4-(2-Morpholin-4-yl-2-oxo-ethyl)-2-oxo-piperazin-1-ylmethyl]-2-thiophen-2-yl-quinoline-4-carboxylic acid ((S)-1-cyclohexyl-ethyl)-amide

a) 4-[4-((S)-1-Cyclohexyl-ethylcarbamoyl)-2-thiophen-2-yl-quinolin-3-ylmethyl]-3-oxo-piperazine-1-carboxylic acid *tert*-butyl ester

- 5 To a solution of 3-oxo-piperazine-1-carboxylic acid *tert*-butyl ester (320 mg, 1.6 mmol) in a mixture of DMF (10 mL) and DMSO (2 mL) at 0°C, sodium hydride (60% in oil, 192 mg, 4.8 mmol) was added. The reaction mixture was stirred at 0°C for 10 min and at room temperature for 30 min. The mixture was re-cooled to 0°C whereupon 3-bromomethyl-2-thiophen-2-yl-quinoline-4-carboxylic acid ((S)-1-cyclohexyl-ethyl)-amide (WO0244165) (731 mg, 1.6 mmol) was added. After the addition was complete, the reaction mixture was stirred at room temperature for 4 hours then partitioned between ethyl acetate and brine. The combined organic phase was washed with brine, dried (MgSO₄), filtered and concentrated. The resulting residue was purified via column chromatography on silica gel using ethyl acetate:
15 hexanes (1:1) as mobile phase to 616 mg of the title compound: LC-MS *m/z* 577.0 (M⁺).

b) 3-(2-Oxo-piperazin-1-ylmethyl)-2-thiophen-2-yl-quinoline-4-carboxylic acid ((S)-1-cyclohexyl-ethyl)-amide, HCl salt

- HCl in dioxane (4.0M, 6.75 mL) was added to 4-[4-[(S)-1-cyclohexyl-ethylamino)-methyl]-2-thiophen-2-yl-quinolin-3-ylmethyl]-3-oxo-piperazine-1-carboxylic acid *tert*-butyl ester (616 mg). The resulting reaction mixture was stirred at room temperature for 3 hours. The solvent was evaporated to give the title compound (624 mg): LC-MS *m/z* 477.2 (M⁺).
20

- c) {4-[4-((S)-1-Cyclohexyl-ethylcarbamoyl)-2-thiophen-2-yl-quinolin-3-ylmethyl]-3-oxo-piperazin-1-yl}-acetic acid ethyl ester
25

- To a solution of 3-(2-oxo-piperazin-1-ylmethyl)-2-thiophen-2-yl-quinoline-4-carboxylic acid ((S)-1-cyclohexyl-ethyl)-amide, HCl salt (600 mg, 1.17 mmol) in acetonitrile (20 mL), N,N-diisopropyl ethylamine (151 mg, 3.51 mmol) and bromoacetic acid ethyl ester (293 mg, 1.75 mmol) were added at room temperature. The
30 reaction mixture was stirred at room temperature for 4 hours. The solvent was

removed under reduced pressure and the residue re-dissolved in ethyl acetate and washed with water. The combined organic phase was washed with brine, dried (MgSO_4), filtered and concentrated to provide 600 mg of title compound: LC-MS m/z 563.2 (M^+).

- 5 d) {4-[4-((S)-1-Cyclohexyl-ethylcarbamoyl)-2-thiophen-2-yl-quinolin-3-ylmethyl]-3-oxo-piperazin-1-yl}-acetic acid

To a solution of {4-[4-((S)-1-cyclohexyl-ethylcarbamoyl)-2-thiophen-2-yl-quinolin-3-ylmethyl]-3-oxo-piperazin-1-yl}-acetic acid ethyl ester (600 mg, 1.06 mmol) in ethanol (20 ml), lithium hydroxide (224 mg, 5.3 mmol) was added. The reaction
10 mixture was stirred at room temperature for 16 hours. The solvent was removed under reduced pressure. Acetic acid (10%) was added to the residue until $\text{pH} = 4$ followed by extraction with ethyl acetate. The combined organic phase was washed with brine, dried (MgSO_4), filtered and concentrated to provide 700 mg of the title compound: LC-MS m/z 535.2 (M^+).

- 15 e) 3-[4-(2-Morpholin-4-yl-2-oxo-ethyl)-2-oxo-piperazin-1-ylmethyl]-2-thiophen-2-yl-quinoline-4-carboxylic acid ((S)-1-cyclohexyl-ethyl)-amide

Following the general procedure described in Example 1c) {4-[4-((S)-1-Cyclohexyl-ethylcarbamoyl)-2-thiophen-2-yl-quinolin-3-ylmethyl]-3-oxo-piperazin-1-yl}-acetic acid (282 mg, 0.53 mmol) was coupled with morpholine (55 mg, 0.53 mmol) to give
20 140 mg of the title compound. LC-MS m/z 604.4 (M^+).

Example 10

3-(4-Dimethylcarbamoylmethyl-2-oxo-piperazin-1-ylmethyl)-2-thiophen-2-yl-quinoline-4-carboxylic acid ((S)-1-cyclohexyl-ethyl)-amide

- 25 Following the general procedure described in Example 9, {4-[4-((S)-1-Cyclohexyl-ethylcarbamoyl)-2-thiophen-2-yl-quinolin-3-ylmethyl]-3-oxo-piperazin-1-yl}-acetic acid (286 mg, 0.53 mmol) was coupled with dimethylamine (2.0 M in THF, 0.53 ml, 1.06 mmol) to give 84 mg of the title compound. LC-MS m/z 562.2 (M^+).

Example 11

6-Fluoro-3-[4-(2-morpholin-4-yl-2-oxo-ethyl)-3-oxo-piperazin-1-ylmethyl]-2-thiophen-2-yl-quinoline-4-carboxylic acid ((S)-1-cyclohexyl-ethyl)-amide

- 5 11a) {4-[4-((S)-1-Cyclohexyl-ethylcarbamoyl)-6-fluoro-2-thiophen-2-yl-quinolin-3-ylmethyl]-2-oxo-piperazin-1-yl}-acetic acid

A solution of 6-Fluoro-3-(3-oxo-piperazin-1-ylmethyl)-2-thiophen-2-yl-quinoline-4-carboxylic acid ((S)-1-cyclohexyl-ethyl)-amide (Prepared in a fashion analogous to {4-[4-((S)-1-Cyclohexyl-ethylcarbamoyl)-2-thiophen-2-yl-quinolin-3-ylmethyl]-2-oxo-piperazin-1-yl}-acetic acid – Example 1c) (35 mg, 0.0734 mmol) in DMF (0.5 mL) was mixed with NaH (5.3 mg, 60% in mineral oil, 0.22 mmol) at room temperature. The resultant mixture was stirred for 3 minutes and mixed with bromoacetic acid ethyl ester (8.1 µL, 0.0734 mmol). After stirring for 1 hr, purification via reverse phase HPLC afforded the title compound (36.5 mg, 90%). MS (ES) *m/z* 553 (M+H)⁺.

10
15

11b) 6-Fluoro-3-[4-(2-morpholin-4-yl-2-oxo-ethyl)-3-oxo-piperazin-1-ylmethyl]-2-thiophen-2-yl-quinoline-4-carboxylic acid ((S)-1-cyclohexyl-ethyl)-amide

A solution of {4-[4-((S)-1-Cyclohexyl-ethylcarbamoyl)-6-fluoro-2-thiophen-2-yl-quinolin-3-ylmethyl]-2-oxo-piperazin-1-yl}-acetic acid (23 mg, 0.0416 mmol) in DMF (0.5 mL) was mixed with morpholine (3.6 µL, 0.0416 mmol), HBTU (15.8 mg, 0.0416 mmol) and 4-methyl-morpholine (8.9 µL, 8.09 mmol). After stirring for 1 hr, purification via reverse phase HPLC afforded the title compound (20 mg, 77%). MS (ES) *m/z* 622 (M+H)⁺.

20
25

Example 12

6-Fluoro-3-[3-oxo-4-(2-oxo-2-pyrrolidin-1-yl-ethyl)-piperazin-1-ylmethyl]-2-thiophen-2-yl-quinoline-4-carboxylic acid ((S)-1-cyclohexyl-ethyl)-amide

The title compound was prepared from {4-[4-((S)-1-Cyclohexyl-ethylcarbamoyl)-6-fluoro-2-thiophen-2-yl-quinolin-3-ylmethyl]-2-oxo-piperazin-1-yl}-acetic acid and pyrrolidine in 58% yield by following the procedure of Example 11b. MS (ES) m/z 606 (M+H)⁺.

5

Example 13

3-{4-[2-((R)-2-Hydroxymethyl-pyrrolidin-1-yl)-2-oxo-ethyl]-3-oxo-piperazin-1-ylmethyl}-2-thiophen-2-yl-quinoline-4-carboxylic acid ((S)-1-cyclohexyl-ethyl)-amide

- 10 Following the general procedure described in Example 1d, {4-[4-((S)-1-Cyclohexyl-ethylcarbamoyl)-2-thiophen-2-yl-quinolin-3-ylmethyl]-2-oxo-piperazin-1-yl}-acetic acid (Example 1c) was coupled with (R)-1-Pyrrolidin-2-yl-methanol to give the title compound (51%). MS (m/z) 618.2 (M⁺), 1.95min.

15 Example 14

3-(4-{[(2,5-Dimethyl-2H-pyrazol-3-ylmethyl)-carbamoyl]-methyl}-3-oxo-piperazin-1-ylmethyl)-2-thiophen-2-yl-quinoline-4-carboxylic acid ((S)-1-cyclohexyl-ethyl)-amide

- 20 Following the general procedure described in Example 1d, {4-[4-((S)-1-Cyclohexyl-ethylcarbamoyl)-2-thiophen-2-yl-quinolin-3-ylmethyl]-2-oxo-piperazin-1-yl}-acetic acid (Example 1c) was coupled with C-(2,5-dimethyl-2H-pyrazol-3-yl)-methylamine to give the title compound (51%). MS (m/z) 642.4 (M⁺), 2.24min.

Example 15

- 25 3-(4-{[(5-Methyl-1H-imidazol-2-ylmethyl)-carbamoyl]-methyl}-3-oxo-piperazin-1-ylmethyl)-2-thiophen-2-yl-quinoline-4-carboxylic acid ((S)-1-cyclohexyl-ethyl)-amide

Following the general procedure described in Example 1d, {4-[4-((S)-1-Cyclohexyl-ethylcarbamoyl)-2-thiophen-2-yl-quinolin-3-ylmethyl]-2-oxo-piperazin-1-yl}-acetic

- acid (Example 1c) was coupled with C-(4-methyl-1H-imidazol-2-yl)-methylamine to give the title compound (43%). MS (m/z) 628.4 (M^+), 1.70min.

Example 16

- 5 3-{4-[(Methyl-thiophen-2-ylmethyl)-carbamoyl]-methyl}-3-oxo-piperazin-1-ylmethyl)-2-thiophen-2-yl-quinoline-4-carboxylic acid ((S)-1-cyclohexyl-ethyl)-amide


- Following the general procedure described in Example 1d, {4-[4-((S)-1-Cyclohexyl-ethylcarbamoyl)-2-thiophen-2-yl-quinolin-3-ylmethyl]-2-oxo-piperazin-1-yl}-acetic acid (Example 1c) was coupled with methyl-thiophene-2-ylmethyl-amine to give the title compound (31%). MS (m/z) 644.2 (M^+), 2.61min.

15

20

What is claimed is:

1. A compound of formula (I)



5

wherein:

R₁ is H or substituted or unsubstituted (C₁₋₆)alkyl;

R₂ is substituted or unsubstituted aryl, (C₃₋₇)cycloalkyl, or heterocycle;

10

R₃ is H or substituted or unsubstituted (C₁₋₆)alkyl, (C₃₋₇)cycloalkyl, aryl or heterocycle;

A is NR₈ or O;

15

R₄ is H or substituted or unsubstituted (C₁₋₆)alkyl;

R₄ is substituted or unsubstituted heterocycle;

20 R₅ is H or up to three substituents independently selected from the list consisting of alkyl, alkenyl, aryl, alkoxy, or a hydroxylated derivative thereof, hydroxy, halogen, nitro, cyano, carboxy, alkylcarboxy, alkylcarboxyalkyl, haloalkyl, amino or mono- or dialkylamino; or R₅ represents a bridging moiety which is arranged to bridge two adjacent ring atoms, wherein the bridging moiety comprises alkyl or dioxyalkylene;

25

R₆ is H or halo;

R₇ is oxo;

n is 1 to 4; or a pharmaceutically acceptable salt thereof.

5

2. A compound according to claim 1 wherein R₁ is methyl.

3. A compound according to claim 1 wherein R₂ is substituted or unsubstituted phenyl or cyclohexyl.

10

4. A compound according to claim 1 wherein R₃ is methyl or substituted or unsubstituted morpholino, piperizine, pyrrole, piperidine, thiophene, imidazole, or pyrazole.

15 5. A compound according to claim 1 wherein R₈ is H or methyl.

6. A compound according to claim 1 wherein R₄ is substituted or unsubstituted 2-thienyl or 3-thienyl.

20 7. A compound according to claim 1 wherein R₅ is H or fluoro.

8. A compound according to claim 1 wherein R₆ is H or fluoro.

9. A compound according to claim 1 which is:

25 3-(4-Dimethylcarbamoylmethyl-3-oxo-piperazin-1-ylmethyl)-2-thiophen-2-yl-quinoline-4-carboxylic acid ((S)-1-cyclohexyl-ethyl)-amide,

3-[4-(2-Morpholin-4-yl-2-oxo-ethyl)-3-oxo-piperazin-1-ylmethyl)-2-thiophen-2-yl-quinoline-4-carboxylic acid ((S)-1-cyclohexyl-ethyl)-amide,

30

3-[3-Oxo-4-(2-oxo-2-piperazin-1-yl-ethyl)-piperazin-1-ylmethyl)-2-thiophen-2-yl-quinoline-4-carboxylic acid ((S)-1-cyclohexyl-ethyl)-amide,

- 3-(4-Carbamoylmethyl-3-oxo-piperazin-1-ylmethyl)-2-thiophen-2-yl-quinoline-4-carboxylic acid ((S)-1-cyclohexyl-ethyl)-amide,
- 5 3-{4-[2-(4-Methyl-piperazin-1-yl)-2-oxo-ethyl]-3-oxo-piperazin-1-ylmethyl}-2-thiophen-2-yl-quinoline-4-carboxylic acid ((S)-1-cyclohexyl-ethyl)-amide,
- 3-[3-Oxo-4-(2-oxo-piperidin-1-yl-ethyl)-piperazin-1-ylmethyl]-2-thiophen-2-yl-quinoline-4-carboxylic acid ((S)-1-cyclohexyl-ethyl)-amide,
- 10 3-[3-Oxo-4-(2-oxo-pyrrolidin-1-yl-ethyl)-piperazin-1-ylmethyl]-2-thiophen-2-yl-quinoline-4-carboxylic acid ((S)-1-cyclohexyl-ethyl)-amide,
- 15 3-[4-(3-Morpholin-4-yl-3-oxo-propyl)-3-oxo-piperazin-1-ylmethyl]-2-thiophen-2-yl-quinoline-4-carboxylic acid ((S)-1-cyclohexyl-ethyl)-amide,
- 3-[4-(2-Morpholin-4-yl-2-oxo-ethyl)-2-oxo-piperazin-1-ylmethyl]-2-thiophen-2-yl-quinoline-4-carboxylic acid ((S)-1-cyclohexyl-ethyl)-amide,
- 20 3-(4-Dimethylcarbamoylmethyl-2-oxo-piperazin-1-ylmethyl)-2-thiophen-2-yl-quinoline-4-carboxylic acid ((S)-1-cyclohexyl-ethyl)-amide,
- 6-Fluoro-3-[4-(2-morpholin-4-yl-2-oxo-ethyl)-3-oxo-piperazin-1-ylmethyl]-2-thiophen-2-yl-quinoline-4-carboxylic acid ((S)-1-cyclohexyl-ethyl)-amide,
- 25 6-Fluoro-3-[3-oxo-4-(2-oxo-2-pyrrolidin-1-yl-ethyl)-piperazin-1-ylmethyl]-2-thiophen-2-yl-quinoline-4-carboxylic acid ((S)-1-cyclohexyl-ethyl)-amide,
- 30 3-{4-[2-((R)-2-Hydroxymethyl-pyrrolidin-1-yl)-2-oxo-ethyl]-3-oxo-piperazin-1-ylmethyl}-2-thiophen-2-yl-quinoline-4-carboxylic acid ((S)-1-cyclohexyl-ethyl)-amide,

3-(4-{[(2,5-Dimethyl-2H-pyrazol-3-ylmethyl)-carbamoyl]-methyl}-3-oxo-piperazin-1-ylmethyl)-2-thiophen-2-yl-quinoline-4-carboxylic acid ((S)-1-cyclohexyl-ethyl)-amide,

5


3-(4-{[(5-Methyl-1H-imidazol-2-ylmethyl)-carbamoyl]-methyl}-3-oxo-piperazin-1-ylmethyl)-2-thiophen-2-yl-quinoline-4-carboxylic acid ((S)-1-cyclohexyl-ethyl)-amide, and

10

3-{4-[(Methyl-thiophen-2-ylmethyl)-carbamoyl]-methyl}-3-oxo-piperazin-1-ylmethyl)-2-thiophen-2-yl-quinoline-4-carboxylic acid ((S)-1-cyclohexyl-ethyl)-amide, or a pharmaceutically acceptable salt thereof.


10. A process for the preparation of a compound of formula (I) according to claim 1 or a salt thereof and/or a solvate thereof, which process comprises reacting a

15 compound of formula (II) or an active derivative thereof:




(II)

20 wherein R'4, R'5, R'6 and X' are R4, R5, R6 and X respectively as hereinbefore defined in relation to formula (I) or a group convertible to R4, R5, R6 and X respectively; with a compound of formula (III):



(III)

wherein R'₁ and R'₂ are R₁ and R₂ as defined for formula (I) or a group or atom convertible to R₁ and R₂ respectively; to form a compound of formula (Ic):




(Ic)

- 5 wherein R'₁, R'₂, X', R'₄, R'₅ and R'₆ are as defined above, and thereafter carrying out one or more of the following optional steps:
- (i) converting any one of R'₁, R'₂, X', R'₄, R'₅ and R'₆ to R₁, R₂, X, R₄, R₅ and R₆ respectively as required, to obtain a compound of formula (I);
 - (ii) converting a compound of formula (I) into another compound of formula (I);
- 10 and
- (iii) preparing a salt of the compound of formula (I) and/or a solvate thereof.
11. A pharmaceutical composition which comprises a compound according to claim 1 and a pharmaceutically acceptable carrier.
- 15 12. A method of treating respiratory diseases in mammals, which comprises administering an effective amount of a compound according to claim 1.

ABSTRACT OF THE DISCLOSURE

Compounds of the formula (I) are disclosed which are NK2 and NK3 receptor antagonists and are useful in the treatment of respiratory diseases:



or a pharmaceutically acceptable salt thereof.

April 27, 2004

PCT DIVISION
34 CHEIMIN DES COLUMBETTES
GENEVA, 1211
GENEVA, 20, SWITZERLAND

This is to inform you that the document requested in your order dated 04-21-2004 is a true reproduction of the official office record copy of that document:

60490452 CERTIFIED PCT APP AS FILED-MAIL 1

- ☐ The enclosed office document is a reproduction from the official office record copy and has been recorded using high quality scanning or microfilm equipment. Copies of page/papers that were not scannable have not been included, nor have pages/papers received after the original filing date. Copies of these pages/papers may be ordered separately.
- ☒ The enclosed document is a reproduction of the best available source of the official office record copy of that document.

If you have any questions or need additional information, please contact our Customer Service Department.

Mailing Address:

Mail Stop Document Services,
Director of the U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

Delivery Address:

U.S. Patent and Trademark Office
Office of Public Records, Customer Service
1213 Jefferson Davis Highway, Suite 300
Arlington VA 22202

Order your copies of USPTO documents on the Web. It's fast, easy, and secure! Go to (<http://ebiz1.uspto.gov/oems25p/index.html>) and order today!

Voice: (703) 308-9726

Fax: (703) 308-7048

E-Mail: <mailto:DSD@USPTO.GOV>

Ref:MS 1161014